Clearstead Advisors’s NovoCure NVCR Stock Holding History

Clearstead Advisors’s Portfolio NVCR Stock Details NVCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-13	Closed	-$169	–	2662
2025 Q4	$169	Sell	13 -274	-95%	-$3.52K	﹤0.01%	2443
2025 Q3	$3.71K	Buy	+287	New	+$3.83K	﹤0.01%	2268
2023 Q3	–	Sell	-25	Closed	-$1.04K	–	1548
2023 Q2	$1.04K	Hold	25	–	–	﹤0.01%	1244
2023 Q1	$1.5K	Hold	25	–	–	﹤0.01%	1183
2022 Q4	$1.83K	Hold	25	–	–	﹤0.01%	1106
2022 Q3	$2K	Hold	25	–	–	﹤0.01%	1087
2022 Q2	$2K	Hold	25	–	–	﹤0.01%	1118
2022 Q1	$2K	Buy	25 +5	+25%	+$368	﹤0.01%	1219
2021 Q4	$2K	Hold	20	–	–	﹤0.01%	1123
2021 Q3	$2K	Hold	20	–	–	﹤0.01%	1140
2021 Q2	$4K	Hold	20	–	–	﹤0.01%	924
2021 Q1	$3K	Buy	20 +10	+100%	+$1.58K	﹤0.01%	925
2020 Q4	$2K	Hold	10	–	–	﹤0.01%	894
2020 Q3	$1K	Buy	+10	New	+$800	﹤0.01%	849

Other funds holding NVCR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

QCM

Quantinno Capital Management New York $59.9B AUM 28.07% 1-Year Est. Return

Clearstead Advisors's NVCR Position: Q1 2026 in Review

Clearstead Advisors sold out of NovoCure (NVCR) in Q1 2026, closing a stake of 13 shares — an estimated $169 sold.

Clearstead Advisors first reported a position in NVCR in Q3 2020 and held it in 14 quarters. The position peaked at $4K in Q2 2021. 222 funds tracked by Wall St. Rank hold NVCR as of Q1 2026.

Clearstead Advisors reported no remaining NovoCure position as of Q1 2026 after selling out during the quarter.
Clearstead Advisors sold 13 NovoCure shares in Q1 2026, an estimated $169.
Clearstead Advisors first reported a position in NovoCure in Q3 2020 and held it in 14 quarters.
Clearstead Advisors's NovoCure position peaked at $4K in Q2 2021.
222 funds tracked by Wall St. Rank held NovoCure as of Q1 2026.

Based on Clearstead Advisors's 13F filing for Q1 2026, filed 6 May 2026.